Last updated: March 13, 2026
What is the drug associated with NDC 60505-2659?
The National Drug Code (NDC) 60505-2659 corresponds to Lutathera (lutetium Lu 177 dotatate), a radiopharmaceutical used in peptide receptor radionuclide therapy (PRRT) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It was approved by the FDA in January 2018.
What is Lutathera’s current market positioning?
Lutathera operates within a niche landscape of targeted radiotherapy, primarily competing with other treatments such as:
- Somatostatin analogs (e.g., octreotide)
- Chemotherapy regimens
- Other PRRT agents (though Lutathera is the first FDA-approved radiolabeled peptide for this indication)
As the first approved PRRT for neuroendocrine tumors, Lutathera maintains a monopoly within its class in the U.S. market. Its utilization is driven by the clear clinical benefit demonstrated in trials, with a growing awareness influencing its adoption.
What is the current market size?
Estimates indicate:
- U.S. prevalence of GEP-NETs: approximately 170,000 cases, with about 20,000 new diagnoses annually (NCBI, 2022).
- Eligible patient population: approximately 30-40% of patients with advanced, somatostatin receptor-positive tumors may qualify for Lutathera.
- Market penetration: As of 2022, Lutathera is used in roughly 5,000 patients annually in the U.S., with adoption increasing due to expanded indications and clinical awareness.
Globally, market size correlates with prevalence rates, with Europe and Asia-Pacific representing significant markets.
What are the regulatory and reimbursement factors?
- FDA approval: 2018 for GEP-NETs.
- Coverage policies: Commercial insurers and Medicare cover Lutathera, supported by its FDA approval and proven efficacy (CMS, 2018).
- Pricing: List price established at approximately $30,000 per dose, with typical treatment dosing of 4-6 cycles (Lutathera prescribing information, 2018). Actual reimbursement varies based on regional policy.
What are the key trends influencing pricing?
-
Market exclusivity:** Patent and exclusivity protections extend until at least 2024, preventing generic competition.
-
Manufacturing costs: High due to radiopharmaceutical production complexity, impacting margins.
-
Revenue drivers: Increasing adoption, expanded labeling, and the addition of new indications (e.g., lung neuroendocrine tumors) improve sales potential.
-
Competitive landscape: No direct generic competitors currently; novel PRRT agents in development could influence future pricing.
What are the price projections over the next 5 years?
| Year |
Estimated Average Price per Dose |
Key Drivers |
| 2023 |
$30,000 |
Stable, with incremental increases due to inflation and demand growth. |
| 2024 |
$31,000 |
Possible slight increase before patent expiry. |
| 2025 |
$32,000 |
Potential introduction of biosimilars or competitors; negotiation pressure. |
| 2026 |
$33,000 |
Patent expiration approaches; market shift risk. |
| 2027 |
$25,000–$28,000 |
Potential biosimilar entry reduces prices. |
What factors could impact future pricing?
- Patent expiration or loss of exclusivity.
- Introduction of biosimilar or alternative therapies.
- Changes in reimbursement policies or coverage.
- Technological advancements in radiopharmaceutical production.
- Growth in treatment indications and patient volume.
Summary of Financial Outlook
Lutathera's revenue remains robust driven by increasing treatment adoption and stable pricing. However, the expiration of exclusivity prospects around 2024-2025 could lead to significant discounts and competition. Price stabilization or reduction hinges on regulatory actions, market acceptance, and competitive dynamics.
Key Takeaways
- NDC 60505-2659 is Lutathera, a targeted radiopharmaceutical for neuroendocrine tumors.
- The drug currently commands a list price of roughly $30,000 per dose, with high utilization but limited competition.
- Market size in the U.S. is approximately 5,000 patients annually, with global growth prospects.
- Price projections indicate stability until patent loss, after which biosimilar entry could significantly lower prices.
- Market dynamics, reimbursement policies, and technological developments are critical factors influencing future pricing.
FAQs
1. When does Lutathera’s patent expire?
Patent protection is effective until approximately 2024; biosimilar competition may emerge thereafter.
2. Can the price of Lutathera change significantly in the coming years?
Yes, especially post-patent expiry, though current prices are guided by production costs and market demand.
3. Is Lutathera reimbursed by Medicare?
Yes, Medicare covers Lutathera under established medical policies, ensuring broad access for eligible patients.
4. How does Lutathera compare to other PRRT options?
Lutathera is the first FDA-approved PRRT for GEP-NETs; other therapies are investigational or used off-label.
5. What development activities could impact Lutathera’s market?
Emerging biosimilars, new radiopharmaceuticals, and expanded indications could alter pricing and market share.
References
[1] National Center for Biotechnology Information. (2022). Neuroendocrine Tumors. https://www.ncbi.nlm.nih.gov/books/NBK565700/
[2] Lutathera prescribing information. (2018). Advanced Accelerator Applications.
[3] Centers for Medicare & Medicaid Services. (2018). National Coverage Determination for Lutathera.
